Industry Newsfasn inhibitoracneascletisphase iii

Ascletis Announces Positive Phase III Results For Denifanstat

manilatimes.net

|January 29, 2026

3.6

Relevance Score

Ascletis Announces Positive Phase III Results For Denifanstat

Ascletis reports positive topline Phase III open-label results for denifanstat (ASC40), a once-daily oral FASN inhibitor for acne. The company says denifanstat demonstrated favorable safety and tolerability in the study.

More AI & Data Science News

Small Language Models Demonstrate On-Prem HR Triage

7.1

Just now

Small Language Models Demonstrate On-Prem HR Triage

Advisors Raise Confidence In Market And Economy

5.2

Just now

Advisors Raise Confidence In Market And Economy

United States Pulls Back From EV Transition

7.2

Back to News Feed

Scoring Rationale

Moderate novelty and segment impact; limited efficacy details and RSS-only source reduce confidence in broader significance.

Sources

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
manilatimes.net
Read Original

Share

Just now

United States Pulls Back From EV Transition

Domo Launches App Catalyst For Pro-Code Apps

8.2

Just now

Domo Launches App Catalyst For Pro-Code Apps

View All News